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Background: Major depressive disorder (MDD) is a debilitating psychiatric illness with a high cost bur-
den. This analysis evaluates the cost-effectiveness of adjunctive brexpiprazole versus comparator bran-
ded adjunctive treatment for MDD and background antidepressant therapy (ADT) alone from a US payer
perspective.
Methods: An economic model was developed to assess the cost-effectiveness of brexpiprazole versus
comparator adjunctive treatment and ADT alone on total direct medical costs using a 6-week cycle time
frame for a total of 48 weeks, with treatment response and remission as primary outcomes. The model
consisted of 3 parts, 1 to represent the acute treatment phase and 2 to represent the maintenance stage.
Results: In the base-case analysis, brexpiprazole as reference treatment resulted in cost per additional
responder ranging from $19,442–$48,745 and cost per additional remitter ranging from $27,196–$71,839
versus comparator treatments over 48 weeks. Sensitivity analyses showed treatment with brexpiprazole
was more costly, but more clinically effective in all probabilistic simulations.
Limitations: This representation of disease natural history over 48 weeks may not account for all possible
health states. Resource utilization on treatment was estimated using the resource use data from previous
trials, and may overestimate medical costs compared to the real-world setting. Treatment comparators
were limited to branded therapies, and head-to-head studies were not available to obtain data inputs.
Conclusion: Compared to other branded adjunctive therapies, brexpiprazole increases response and re-
mission at 6 weeks; medical care cost savings were observed with the use of brexpiprazole. These
ﬁndings may assist clinicians and formulary decision makers when selecting treatment for MDD.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Major depressive disorder (MDD) is a widespread, debilitating
psychiatric illness (Gelenberg et al., 2010) that has a lifetime pre-
valence of approximately 16% and annual prevalence of 6.6% in the
US (Kessler et al., 2003, 2005). In a 2010 study, depressive dis-
orders ranked second in global disability burden (Ferrari et al.,
2013) and US cost burden of MDD for 2010 was estimated at
$210.5 billion and increased by 21.5% from 2005 to 2010 (Green-
berg et al., 2015; Kessler, 2012). There are a variety of monotherapy
pharmacotherapies for treating MDD. These therapies fall into
pharmacological classes which include tricyclic antidepress-B.V. This is an open access article u
tsuka Pharmaceutical Devel-
Princeton, NJ 08540, United
.S. Aigbogun).ants, selective serotonin reuptake inhibitors (SSRI), selective nor-
epinephrine reuptake inhibitors (SNRI), selective serotonin and
norepinephrine reuptake inhibitors, tetracyclic antidepressants
(non-selective serotonin and norepinephrine reuptake inhibitors),
monoamine oxidase inhibitors (irreversible and reversible in-
hibitors), agonists of the melatonin receptor, and other anti-
depressants (Zimovetz et al., 2012).
MDD therapy success is generally measured by response, al-
though the ultimate goal of therapy is remission (Nierenberg and
DeCecco, 2001; Gaynes et al., 2015). Approximately 50% of patients
with MDD do not achieve adequate response to ﬁrst-line anti-
depressant treatment (ADT) and nearly 30% do not beneﬁt from
trying a series of monotherapy treatments (Nierenberg et al.,
2003; Han et al., 2013; Papakostas, 2009; Rush et al., 2006; Fava
et al., 2006). In addition, only 27–39% of patients in a real-world
setting achieve remission (Cuffel et al., 2003). Inadequate re-
sponses or increasing lines of therapies increases the overallnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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et al., 2009; Simon et al., 2006; Mauskopf et al., 2009; Knoth et al.,
2010).
Effective treatment for patients with MDD who do not respond
adequately remains an important unmet need (Connolly and
Thase, 2011; Han et al., 2013). Atypical antipsychotics (AAPs) are
often used as adjunctive therapies for MDD. Following inadequate
response to ADT, the current guidelines recommend switching
ADT, adding a second ADT, or adding adjunctive therapy with a
non-ADT (American Psychiatric Association, 2010; Patkar and Pae,
2013). Although AAPs can lead to adverse event (AE) risks, in-
cluding extrapyramidal symptoms as well as metabolic syndrome
and diabetes (Cha and McIntyre, 2012; Nelson and Papakostas,
2009; Gao et al., 2011), early adjunctive treatment with AAPs may
reduce the cost burden for patients with MDD. Following the
failure of initial trials with an ADT, early adjunctive treatment with
an AAP lowered resource use and costs compared with patients
who continued with monotherapy treatment trials (Legacy et al.,
2015).
Brexpiprazole is an effective AAP-approved in the US by the
FDA in July 2015 for adjunctive treatment of MDD (Thase et al.,
2015a, 2015b; Otsuka Pharmaceutical Co., Ltd, 2015). Efﬁcacy of
brexpiprazole as an adjunct treatment of MDD was evaluated in
two 6-week, placebo-controlled, ﬁxed-dose pivotal trials of adult
patients with MDD, with or without symptoms of anxiety, who
had an inadequate response to 1–3 courses of a prior ADT in the
current episode, as well as a demonstrated inadequate response
throughout the 8 weeks of prospective ADTs (Thase et al., 2015a,
2015b). Adjunctive treatment with brexpiprazole signiﬁcantly
improved the mean Montgomery-Asberg Depression Rating Scale
(MADRS) total scores of these patients. The incidence of activating
treatment-emergent AEs (akathisia, insomnia, anxiety, and rest-
lessness) was low, as was the incidence of sedating AEs (sedation,
somnolence, and hypersomnia). A moderate weight increase was
observed during treatment with adjunctive brexpiprazole, with
small changes in metabolic parameters (Thase et al., 2015a, 2015b).
Evidence of efﬁcacy and tolerability remain important in the
evaluation and comparison of available therapies; however, it is
also important to determine cost-effectiveness of these therapies,Table 1
Clinical event rates: response, remission, and all-cause treatment discontinuation.
Parameter and treatment Relative rate (vs. respective
placebo)
Derived rate (%) P
MADRS response at 6 weeks
Brexpiprazole 2 mg 1.49 48.45% B
Quetiapine XR 150 mg/day 1.16 37.82% B
Quetiapine XR 300 mg/day 1.26 41.05% B
Olanzapine/ﬂuoxetine 1.28 41.77% B
Pooled ADT N/A 32.53% B
MADRS remission at 12 weeksa
Brexpiprazole 2 mg 1.65 46.21% B
Quetiapine XR 150 mg/day 1.30 38.57% B
Quetiapine XR 300 mg/day 1.44 41.65% B
Olanzapine/ﬂuoxetine 1.49 42.75% B
Pooled ADT N/A 31.91% B
All-cause treatment discontinuation
Brexpiprazole 2 mg 1.09 15.29% B
Quetiapine XR 150 mg/day 1.32 18.51% B
Quetiapine XR 300 mg/day 1.82 25.41% B
Olanzapine/ﬂuoxetine 1.18 16.43% B
Pooled ADT N/A 13.98% B
ADT, antidepressant therapy; MADRS, Montgomery-Asberg Depression Rating Scale; PS
a Based on clinical guidance, derived remission rates and then pooled ADT remissiogiven limitations on healthcare spending. The objective of the
present analysis was to evaluate the cost-effectiveness of ad-
junctive brexpiprazole versus comparator-branded adjunctive
treatment for MDD, and background ADT alone, in the US
healthcare setting, from a payer perspective. Speciﬁcally, MDD-
related healthcare costs, as well as the number of patients
achieving response and remission were estimated over a 48-week
time horizon, and the results were used to estimate both the in-
cremental cost per additional responder and per additional re-
mitter. While a signiﬁcant number of models evaluating the cost-
effectiveness of alternative MDD strategies have been developed
(Zimovetz et al., 2012), few models have assessed adjunctive AAPs
for MDD treatment. Evaluating the cost-effectiveness of newly
available branded treatments in MDD can shape policies con-
cerning treatment coverage and reimbursement. In the case of oral
antipsychotics, the majority of the treatments are available gen-
erically in the US. Given the cost pressures from payers, it is to be
expected that generic drug utilization precedes the use of other
available branded agents. Hence, for policy makers to evaluate
new branded products for formulary placement, an appropriate
analysis would involve comparisons of the newly available bran-
ded product with other available branded drugs.2. Methods
2.1. Model description
An economic model was constructed to assess the impact of
brexpiprazole versus comparator adjunctive treatment and ADT
alone on total costs (direct medical plus pharmacy costs), focusing
on treatment response and remission as primary outcomes. The
model was programmed using Microsoft Excel 2010 and estimated
cost-effectiveness from a US payer perspective. The model used a
6-week cycle time frame based on the length of treatment in the
brexpiprazole pivotal trial and the minimum duration of com-
parator pivotal trials (Table 1). Clinical trials in MDD are often
conducted over a period of 6–8 weeks, representing the acute
phase of a depressive disorder (Zimovetz et al., 2012).SA distribution Source
eta Thase, 2015a
eta Bauer, 2009; El-Khalili, 2010
eta Bauer, 2009; El-Khalili, 2010
eta Shelton 2001; Shelton, 2005; Thase et al., 2007
eta Shelton, 2001; Shelton 2005; Thase et al., 2007; Bauer, 2009;
El-Khalili, 2010; Thase, 2015a
eta Thase, 2015a
eta Bauer, 2009; El-Khalili, 2010
eta Bauer, 2009; El-Khalili, 2010
eta Shelton, 2001; Shelton, 2005; Thase et al., 2007
eta Shelton 2001, Shelton, 2005; Thase et al., 2007; Bauer, 2009;
El-Khalili, 2010; Thase, 2015a
eta Thase, 2015a
eta Bauer, 2009; El-Khalili, 2010
eta Bauer, 2009; El-Khalili, 2010
eta Shelton, 2001; Shelton, 2005; Thase et al., 2007
eta Shelton, 2001; Shelton, 2005; Thase et al., 2007; Bauer, 2009;
El-Khalili, 2010; Thase, 2015a
A, probability sensitivity analysis.
n rates were given an additional 10%.
Fig. 1. Model diagram. Treatment include brexpiprazole 2 mg, ADT, olanzapine/ﬂuoxetine, quetiapine XR 150 mg/day, quetiapine XR 300 mg/day. ADT, antidepressant
therapy.
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treatment phase and the latter two representing the maintenance
phase (Fig. 1)—both phases consisted of treatment either with
adjunct therapy or ADT therapy alone. The acute treatment phase
consisted of an initial 6-week decision analytic portion matching
the pivotal trial duration to measure response. A second 6-week
decision analytic phase measured remission and a third portion
(Markov model) measured relapse and was composed of six
6-week cycles. Thus, the model horizon was limited to 48 weeks
(8  6‐week cycles), due to lack of comparable long-term pub-
lished data.
The initial model population was representative of patient
characteristics entering the prospective phase of the brexpiprazole
pivotal trial (Thase et al., 2015a), which included male or female
patients aged 18–65 years, diagnosis of single or recurrent non-
psychotic MDD episode Z8 weeks, and an inadequate response
(deﬁned as o50% reduction in Antidepressant Treatment History
Questionnaire score to an adequate trial of between 1–3 ADTs).
These patients demonstrated HAM-D17 total scores Z18 both at
screening and on the ﬁrst day of treatment phase. Prior to ran-
domization to brexpiprazole, patients had to demonstrate a per-
sistent inadequate response to 8 weeks of prospective treatment
with selected SSRIs or SNRIs, deﬁned as HAM-D 414 and o50%
reduction in HAM-D, as well as o50% reduction in MADRS score
and CGI Z3 at each visit.
In the model, treatment options included the following bran-
ded oral AAP therapies: brexpiprazole 2 mg/day; quetiapine XR
150 mg/day; quetiapine XR 300 mg/day; olanzapine/ﬂuoxetine—6,
12, or 18 mg/day olanzapine with ﬂuoxetine 50 mg/day; as well as
ADT alone (deﬁned as placebo arm of comparator trials). Olanza-
pine/ﬂuoxetine is indicated for patients with treatment-resistant
depression and, more speciﬁcally, for acute treatment of adult
patients with MDD who have not responded to two separate trials
of different antidepressants of adequate dose and duration in their
current episode. While the criteria for inadequate response to
treatment in the brexpiprazole, quetiapine XR, and olanzapine/
ﬂuoxetine trials were not the same, olanzapine/ﬂuoxetine was still
considered an appropriate comparator intervention in the model
because of its inclusion in the most recent AAP cost-effectiveness
analysis (Taneja et al., 2012) and per clinical experts’ opinions.
Patients entered the model following initiation of adjunct
treatment and progressed through the initial decision tree com-
ponent (acute phase of treatment, Fig. 1). Following treatment
initiation, patients were exposed to AE risk and all-cause dis-
continuation during the ﬁrst 6 weeks. Based on expert opinion
(Edwards et al., 2013), the incidence of AEs and treatment dis-
continuation were considered either instantaneous or occurring
between 2–6 weeks, and were therefore assumed in the model to
occur in the initial treatment period only. At the end of the initialphase, patients who responded continued to the next phase and
those who did not respond remained in non-response for the
model duration and were assumed to be assigned to discontinue
adjunctive treatment and to continue current ADT or move to al-
ternative therapy.
Patients not responding to, or discontinuing treatment from
their acute treatment, were assumed to have no further beneﬁt
from their comparator augmentation therapy and were assigned to
a standard package of care (average daily augmentation cost plus
physician ofﬁce visit per cycle) and patients who responded but
did not remit were assumed to continue comparator treatment
alongside standard care (Edwards et al., 2013).
In the second part of the model (start of maintenance period,
Fig. 1), responders who entered remission subsequently entered
the Markov portion while “no-remission” patients remained in
their health state for the rest of the model. In the third part of the
model, patients either remained in the remission health state or
moved to relapse, based on associated risk. Deﬁnitions of remis-
sion and response are variable across studies in the literature and
present challenges in performing indirect comparisons of inter-
ventions where no head-to-head studies exist (Zimovetz et al.,
2012; Citrome, 2010). In the current model, response was deﬁned
as the proportion of patients who, at 6 weeks, had a reduction in
their MADRS score of at least 50% from baseline, which is a stan-
dard deﬁnition of response (Nierenberg, 2001). Remission has
been deﬁned as “at least 3 weeks of the absence of both sad mood
and reduced interest and no more than three remaining symptoms
of the major depressive episode” (Gelenberg et al., 2010). In the
brexpiprazole pivotal trial, the deﬁnition for remission was both a
MADRS total score of r10, and a Z50% reduction from baseline in
MADRS total score; for the quetiapine and olanzapine/ﬂuoxetine
studies, the deﬁnition was MADRS score of r10 (Table 1). Based
on discussions with clinical experts, evenwith differing deﬁnitions
for remission, patients remitting were considered to have had a
satisfactory response.
2.2. Model estimation
Data inputs for the model were derived from the brexpiprazole
pivotal trial and comparator trial reports, abstracted from sec-
ondary sources including meta-analyses, and derived from pro-
duct labeling. The brexpiprazole pivotal trial (Thase, 2015a) study
was selected because this trial evaluated and reported results for
patients on the 2 mg recommended effective dose for brexpipra-
zole. Clinical parameters include response and remission rates and
all-cause discontinuation rates (Table 1) as well as AE rates from
the Thase 2015a study (Table 2). Derived rates were calculated for
clinical inputs including response, remission, and all-cause dis-
continuation, allowing for a more accurate comparison of clinical
Table 2
Absolute rate of adverse events (AEs).
Parameter Treatment Absolute
rate, %
PSA
distribution
Source
Akathisia Brexpiprazole 2 mg 7.45% Beta Thase, 2015a
Quetiapine XR 150 mg 1.35% Beta Bauer, 2009; El-Khalili, 2010
Quetiapine XR 300 mg 2.68% Beta Bauer, 2009; El-Khalili, 2010
Olanzapine/ﬂuoxetine 2.85% Beta Shelton, 2001; Shelton, 2005; Thase et al., 2007
Pooled ADT 2.85% Beta Thase, 2015a; Shelton, 2001; Shelton, 2005; Thase et al., 2007; Bauer, 2009; El-Khalili, 2010
Fatigue Brexpiprazole 2 mg 1.60% Beta Thase, 2015a
Quetiapine XR 150 mg 14.29% Beta Bauer, 2009; El-Khalili, 2010
Quetiapine XR 300 mg 10.90% Beta Bauer, 2009; El-Khalili, 2010
Olanzapine/ﬂuoxetine 14.00% Beta Shelton, 2001; Shelton, 2005; Thase et al., 2007
Pooled ADT 4.06% Beta Thase, 2015a; Shelton, 2001; Shelton, 2005; Thase et al., 2007; Bauer, 2009; El-Khalili, 2010
Somnolence Brexpiprazole 2 mg 4.26% Beta Thase, 2015a
Quetiapine XR 150 mg 22.54% Beta Bauer, 2009; El-Khalili, 2010
Quetiapine XR 300 mg 25.96% Beta Bauer, 2009; El-Khalili, 2010
Olanzapine/ﬂuoxetine 17.50% Beta Shelton, 2001; Shelton, 2005; Thase et al., 2007
Pooled ADT 2.93% Beta Thase, 2015a; Shelton, 2001; Shelton, 2005; Thase et al., 2007; Bauer, 2009; El-Khalili 2010
Weight gain Brexpiprazole 2 mg 7.98% Beta Thase, 2015a
Quetiapine XR 150 mg 3.17% Beta Bauer, 2009; El-Khalili, 2010
Quetiapine XR 300 mg 5.19% Beta Bauer, 2009; El-Khalili, 2010
Olanzapine/ﬂuoxetine 35.00% Beta Shelton, 2001; Shelton, 2005; Thase et al., 2007
Pooled ADT 2.08% Beta Thase, 2015a; Shelton et al., 2001; Shelton et al., 2005; Thase et al., 2007; Bauer et al., 2009;
El-Khalili et al., 2010
ADT, antidepressant therapy; AE, adverse event; PSA, probability sensitivity analysis.
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lated as the product between the relative clinical rate within trial
(active vs. respective placebo) and a pooled placebo clinical rate. InTable 3
Estimated cost inputs.
Type and parameter Estimate PSA distribution Sour
Health state
Response $195.80 Gamma Ivano
No response (cycle 1) $322.04 Gamma Ivano
No response (cycle 2–8) $126.24a Gamma Edwa
Remission $99.98b Gamma Sobo
No remission (cycle 2–8) $195.80 Gamma Edwa
Relapse $226.22 Gamma Ivano
No relapse $99.98b Gamma Sobo
Treatment discontinuation
All-cause (cycle 1) $322.04 Gamma Ivano
All-cause (cycles 2–8) $126.24a Gamma Tanej
Adverse events
Fatigue, somnolence, and weight gain $126.24a Uniform Tanej
Akathisia pharmacotherapy and ofﬁce visit $129.46 Uniform Tanej
Akathisia pharmacotherapy per day $0.08c Uniform Red B
Akathisia ofﬁce visit $126.24 Uniform Tanej
Background antidepressant treatment
Weighted cost per day $5.24 Uniform Red B
ResouEscitalopram, 18.7 mg $0.23 NA
Fluoxetine, 35.1 mg $0.78 NA
Paroxetine CR, 48.2 mg $7.40 NA
Sertraline, 152.3 mg $0.22 NA
Venlafaxine XR, 193.3 mg $16.23 NA
Duloxetine, 58.3 mg $6.28 NA
Adjunctive product
Brexpiprazole, average daily cost $28.85 Uniform Otsuk
Quetiapine 150 mg/day, average daily cost $13.65 Uniform Analy
Quetiapine 300 mg/day, average daily cost $19.70 Uniform Analy
Olanzapine/ﬂuoxetine, average daily cost $14.34 Uniform Red B
Average adjunctive treatment, average daily
cost
$25.62 Uniform Red B
Resou
a Cost of additional ofﬁce visit.
b Assumption of 48.9% reduction in standard cost assigned for remitters (distributio
c Product and average daily dose: lorazepam, 1 mg ($0.05); propanolol, 10 mg ($0.04)
probability sensitivity analysis.the model, an additional 10% of patients were assumed to go into
remission during the second 6-week cycle based on medical ex-
pert opinion, and the relapse rate used to represent comparatorce
va et al., 2010
va, 2010; Taneja, 2012
rds, 2013; Taneja, 2012
cki et al., 2007; Ivanova, 2010
rds, 2013
va, 2010; Taneja, 2012
cki et al., 2007; Ivanova, 2010
va, 2010; Taneja, 2012
a, 2012; Edwards, 2013
a, 2012
a, 2012
ook Pricing
a, 2012
ook Pricing; IHS Global Pricing and Reimbursement, AnalySource Drug Pricing
rce, 2015; Taneja, 2012
a America Pharmaceutical, Inc.
Source Drug Pricing Resource, 2015
Source Drug Pricing Resource, 2015
ook Pricing
ook Pricing; IHS Global Pricing and Reimbursement; AnalySource Drug Pricing
rce, 2015
n¼uniform).
; benztropine mesylate, 1 mg ($0.14). NA, not applicable (i.e., were not varied); PSA,
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Clinical values from pivotal trials extending beyond 6 weeks
were extrapolated to corresponding 6-week values using Kaplan-
Meier curves where appropriate, AE rates were pooled as needed
(Spielmans et al., 2013), and absolute rates of AEs across com-
parator trials were used. For all comparator trials, a literature-
based rate of relapse of 11% was used and extrapolated to a proper
6-week 2.68% rate (Gilchrist and Gunn, 2007).
Cost parameters were derived from the literature and included
standard MDD care, ADT and adjunctive drug acquisition, patients
entering response, patients entering remission, patients experi-
encing a relapse, treatment discontinuation, and treatment costs
for AEs (Table 3). Costs were inﬂated to 2014 price levels using the
Medical Care component of the Consumer Price Index. In the ﬁrst
6-week cycle, patients were assigned standard care costs, which
were comprised of direct medical costs. Patients with no response
were assigned an additional ofﬁce visit cost. Remission care costs
were calculated according to a literature-based percentage re-
duction in standard care costs. Patients under “no-remission” were
assigned standard care costs and continued to receive adjunctive
drug therapy; patients in remission who later relapsed were as-
signed a one-time cost of a physician ofﬁce visit in addition to
standard care costs and immediately left the model. Product ac-
quisition costs included the cost of adjunctive intervention as-
signed in each cycle and ADT cost input, which was based on the
mean dosages of the various ADTs utilized in the brexpiprazole
pivotal trial, weighted by the proportion of patients receiving each
agent in the trial. Patients experiencing an AE were assigned a
physician ofﬁce visit cost and pharmacotherapy as applicable;
those who discontinued were assigned an ofﬁce visit cost as well
as average adjunctive treatment costs in all subsequent cycles.
2.3. Analysis
Total direct MDD-related healthcare costs and incremental
costs, as well as clinical improvement of additional responder and
remitter, were estimated for each product in the model. Incre-
mental cost-effectiveness ratios (ICERs) were expressed as the cost
per additional responder and also as the cost per additional pa-
tient entering remission. The cost per additional responder and
remitter versus comparator treatment was calculated at the end of
the last cycle (week 48) as the ratio of the difference between the
cost of MDD-related care in patients receiving adjunctive brexpi-
prazole versus alternative treatment, to the difference in the
number of patients achieving response or remission, respectively.
2.4. Sensitivity analyses
One-way sensitivity analyses were performed to assess the
robustness of the results to changes in key parameters. WhileTable 4
Base-case cost-effectiveness results: cost per additional responder and per additional re
Treatment strategy MDD-related care
expected cost per
person
Incremental
cost
Cost per additional res
Estimated number
of responders
Incr
ber
Brexpiprazole 2 mg $11,511 Reference 484 Ref
Quetiapine XR
150 mg/day
$9082 $2429 378 106
Quetiapine XR
300 mg/day
$10,072 $1439 411 74
Olanzapine/
ﬂuoxetine
$8256 $3255 418 67
ADT $7255 $4257 325 159
ADT, antidepressant therapy; MDD, major depressive disorder.holding the other parameters ﬁxed, brexpiprazole cost-speciﬁc
input parameters were adjusted by a ﬁxed 10% above and below
the base input values to produce low and high estimates of the
clinical and economic outputs. In addition, sensitivity analyses
were performed for the clinical parameters of response rate, re-
mission rate, and relapse rate, as well as rates of AEs, including
akathisia, fatigue, somnolence, and weight gain.
To assess uncertainty in the cost-effectiveness analysis, a
probabilistic sensitivity analysis (PSA) was also conducted using a
second-order Monte Carlo simulation. The PSA was performed by
simultaneously drawing from appropriate distribution functions
for all model parameters according to their means and distribu-
tions (Tables 1–3). Mean, high, and low estimates were obtained
from the publication of each model input, when available. All rates
were varied using a beta distribution, and costs were varied using
a gamma distribution. For costs where a conﬁdence interval was
not provided, inputs were sampled from a uniform distribution.
This process of drawing parameters and running the model was
repeated 5000 times, and results (i.e., mean and 95% conﬁdence
intervals [CI]) were used to evaluate the robustness of model
outcomes when varying all input estimates. Additionally, results
are presented graphically in scatter plots displaying incremental
costs and effects (i.e., responders, remitters), both in aggregate.
Lastly, scenario analyses were conducted to assess the impact of
alternative time horizons and estimate assumptions on AEs.3. Model results
3.1. Clinical outcomes
In a hypothetical cohort of 1000 patients with inadequate re-
sponse to ADT, the model-estimated number of clinical responders
after 6 weeks of adjunctive therapy was higher for brexpiprazole
compared with quetiapine 150 mg/day, quetiapine 300 mg/day,
olanzapine/ﬂuoxetine, and ADT alone at 484 vs. 378, 411, 418, and
325 respectively at 48 weeks (Table 4). In addition, the estimated
number of clinical remitters was higher for brexpiprazole com-
pared with quetiapine 150 mg/day, quetiapine 300 mg/day, olan-
zapine/ﬂuoxetine, and ADT alone, at 224 versus 146, 171, 179, and
104 respectively (Table 4).
3.2. Costs
Expected total costs (medical and pharmacy) per patient over
48 weeks were estimated to be $7255 for ADT alone, $8256 for
olanzapine/ﬂuoxetine, $9082 for quetiapine 150 mg/day, $10,072
for quetiapine 300 mg/day, and $11,511 for brexpiprazole (Table 4,
Fig. 2A). In patients with inadequate response to ADT, the model
demonstrated that those receiving adjunct treatment withmitter.
ponder Cost per additional remitter
emental num-
of responders
ICER Estimated num-
ber of remitters
Incremental num-
ber of remitters
ICER
erence Reference 224 Reference Reference
$22,852 146 78 $31,132
$19,442 171 53 $27,196
$48,745 179 45 $71,839
$26,737 104 120 $35,445
Fig. 2. Total costs (A) and medical costs (B) per patient over 48 weeks; medical
costs include those related to patient monitoring, treatment discontinuation, and
AE-related treatment. Note: Light grey bars are incremental costs over medical
costs for patients receiving adjunct brexpiprazole. ADT, antidepressant therapy.
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related to patient monitoring, treatment discontinuation, and AE-
related treatment) compared with those receiving other therapies
(Fig. 2B). Overall, increased care-related medical costs ranged from
$586 for olanzapine/ﬂuoxetine to $1195 for ADT alone.
3.3. Cost per responder
Using brexpiprazole as the reference treatment, cost per addi-
tional responder in the base case ranged $19,442–$48,745 at 48
weeks (Table 4). Sensitivity analyses for cost per additional re-
sponder demonstrated that the cost of brexpiprazole and the rate
of clinical response were the most inﬂuential variables, attributing
the greatest sensitivity in the analysis (see Supplemental Table 1
for full analysis). Speciﬁcally, when the cost of brexpiprazole was
varied by 710%, cost per additional responder estimates ranged
$19,726–$25,977 for quetiapine XR 150 mg/day, $14,953–$23,930
for quetiapine XR 300 mg/day, $43,772–$53,719 for olanzapine/
ﬂuoxetine, and $24,651–$28,823 for ADT alone. Additionally, when
the brexpiprazole rate of clinical response was varied by 710%,
cost per additional responder estimates ranged $16,408–$40,092
for quetiapine XR 150 mg/day, $12,649–$51,997 for quetiapine XR
300 mg/day, $29,206–$171,584 for olanzapine/ﬂuoxetine, and
$21,029–$37,439 for ADT alone. Probabilistic sensitivity analysis
resulted in mean (95% CI) cost per additional responder of $22,062
($14,761-$31,964) for quetiapine XR 150 mg/day; $18,770 ($9236-
$32,420) for quetiapine XR 300 mg/day; $41,148 ($24,806–
$68,778) for olanzapine/ﬂuoxetine; and $25,980 ($19,904–
$33,792) for ADT alone. The scatter plot displayed in Supplemental
Fig. 1 illustrates that all combinations of incremental costs and
incremental numbers of responders are in the upper right quad-
rant, which represents a situation where treatment with brexpi-
prazole is more costly, but also results in more responders. Thisoccurs in 100% of the cases when brexpiprazole is compared with
quetiapine XR 150 mg/day, olanzapine/ﬂuoxetine, and ADT alone,
and quetiapine XR 300 mg/day.
3.4. Cost per remitter
Using brexpiprazole as the reference treatment, cost per addi-
tional remitter in the base case ranged $27,196–$71,839 at 48
weeks (Table 4). Sensitivity analyses for cost per additional re-
mitter demonstrated that cost of brexpiprazole, the rate of clinical
response, the rate of clinical remission, and the rate of dis-
continuation were all inﬂuential variables attributing to the
greatest sensitivity in the analysis (see Supplemental Table 1 for
full analysis). Probabilistic sensitivity analysis resulted in a mean
(95% CI) cost per additional remitter of $33,895 ($24,117–$45,763)
for quetiapine XR 150 mg/day; $29,365 ($14,829–$48,270) for
quetiapine XR 300 mg/day; $67,929 ($43,018–$103,546) for olan-
zapine/ﬂuoxetine; and $38,937 ($32,215–$46,740) for ADT alone.
The scatter plot displayed in Supplemental Fig. 2 shows similar
results to the scatter plot in Supplemental Fig. 1, namely that all
combinations fall in the upper right quadrant.
3.5. Scenario analyses
In a 6-week model time horizon scenario analysis, expected
total cost of MDD-related care was estimated to be $561 for ADT
alone, $1012 for olanzapine/ﬂuoxetine, $1180 for quetiapine
150 mg/day, $1456 for quetiapine 300 mg/day, and $1769 for
brexpiprazole. Using brexpiprazole as the reference treatment,
cost per additional responder was $11,334 versus olanzapine/
ﬂuoxetine, $5547 versus quetiapine 150 mg/day, $4229 versus
quetiapine 300 mg/day, and $7587 versus ADT alone.
Notably, adverse event rates were incorporated into the model
by using absolute estimates from comparator trials. To assess the
impact of using derived rates of AEs in the model (similar to de-
rived rate calculations for response, remission, and all-cause dis-
continuation), a second scenario analysis was conducted. The
calculated derived rates are presented in Supplemental Table 2. In
this scenario, using a 6-week time horizon, the total cost per pa-
tient for MDD-related care was estimated to be $560 for ADT
alone, $968 for olanzapine/ﬂuoxetine, $1187 for quetiapine
150 mg/day, $1468 for quetiapine 300 mg/day, and $1798 for
brexpiprazole. The cost per additional responder for brexpiprazole
versus quetiapine XR 150 mg/day was $5753, versus quetiapine XR
300 mg/day was $4464, versus olanzapine/ﬂuoxetine was $12,435,
and versus ADT alone was $7774. The results from this scenario
using derived rates of AEs shows consistent ﬁndings—both in
terms of magnitude and trending—with the base case analyses in
which absolute AE rates were used.4. Discussion
Model results suggested treatment with brexpiprazole, as an
adjunctive treatment for MDD may lead to clinical beneﬁts in
terms of response and remission, as well as medical cost savings.
When evaluating the cost per additional responder, compared to
brexpiprazole as the reference, base case estimates ranged from
$19,442–$48,745 at 48 weeks for comparator treatments and es-
timates ranged from $4229–$11,334 at 6 weeks. Likewise, base
case estimates ranged from $27,196–$71,839 at 48 weeks for al-
ternative treatments for cost per additional remitter using brex-
piprazole as the reference treatment.
Previous studies predominantly analyzed cost-effectiveness of
SSRIs. As a reference point, one US economic analysis using re-
mission as an endpoint reported an ICER of venlafaxine XR
M. Sussman et al. / Journal of Affective Disorders 207 (2017) 54–6260compared with generic SSRIs was $2073 per patient achieving
remission, followed by $3566 for escitalopram over a 6-month
treatment time frame (Malone, 2007). The perspective used was a
managed care organization (MCO), and wholesale acquisition cost
prices used reﬂected MCO costs for generics and branded agents.
The results in the current study support previous reports that
adjunctive treatment with an AAP is a cost-effective treatment
strategy for MDD treatment in patients with documented in-
adequate response, however there are very few studies published
that report ICERs for treatment with AAPs. A study using a lifetime
horizon showed that patients treated with aripiprazole spent less
time in major depressive episodes, had an improvement in quality
of life and had a cost savings of 593 Turkish lira (TL, 209 current
USD) versus quetiapine and 485 TL (171 current USD) versus
olanzapine (Saylan et al., 2013). An additional AAP cost-effective-
ness study in which the reference was ADT and time frame was
6 weeks, reported cost per additional responder at $3447 for ar-
ipiprazole for the 6 weeks, which was lower compared to que-
tiapine 150 mg/day, quetiapine 300 mg/day, or olanzapine/ﬂuox-
etine at $8725, $6000, and $3993 (Taneja et al., 2012). In contrast,
augmentation with lithium demonstrated a modest cost savings
compared with AAPs in a UK economic analysis (cost saving of
d905 per year, at approximately $1278 current USD) (Edwards
et al., 2013). Notably, a literature review in 2012 compared pub-
lished cost-effectiveness studies in MDD and found a need for
further studies in patients with MDD who have partial or no re-
sponse to ﬁrst-line therapies and suggested that more studies on
adjunctive MDD therapies would be welcome (Zimovetz et al.,
2012).
As stated, cost-effectiveness studies in MDD are more com-
monly observed in assessing ADT as monotherapy and in these
studies, both response and remission have been used in the ana-
lyses (Nordstrom et al., 2010; Trivedi et al., 2004; Benedict et al.,
2010; Malone, 2007; Lenox-Smith et al., 2009). Therapy for MDD
treatment is often measured in terms of response which can be
deﬁned as a clinically meaningful degree of symptom reduction,
although the ultimate goal of MDD therapy is remission (deﬁned
as being free of depressive symptoms with a return to normal
functioning) (Nierenberg et al., 2001; Gaynes et al., 2015). Al-
though it is known that the deﬁnitions of remission are not always
consistent between studies, which can make comparisons difﬁcult
(Zimovetz et al., 2012), the current analysis has the advantage over
other cost-effectiveness analyses in that it presents the cost-ef-
fectiveness of treatments for incremental costs both as per addi-
tional responder and per additional remitter. Another notable
distinction is that the current analysis spans a 48-week time
frame, whereas most monotherapy ADT cost-effective analyses
and the few published AAP models were developed using either a
lifetime horizon or a 6-week time frame. It is difﬁcult to compare
results, given the varying time horizons and assumptions used
across models.
The model results are subject to several limitations including
the necessary assumptions implemented as detailed in the
Methods section. Namely, based on the literature, incidence of AEs
and treatment discontinuation were assumed to occur only within
the ﬁrst 6 weeks (Edwards et al., 2013). It is possible, however, that
some AEs (such as sedation) may occur throughout treatment,
which would not be accounted for in this model. Therefore, by
limiting AEs to a single occurrence, the model may underestimate
the costs and impact of these AEs in the full 48 weeks modeled.
However, although the included AEs may have been limited, our
study is one of the few studies that included AEs in the model.
Also, due to a deﬁciency of data on discontinuation among com-
parator therapies, conservative assumptions were made regarding
maintenance therapy and associated costs for those that dis-
continued treatment, which may affect the results (Edwards et al.,2013). Another limitation is that, due to the study design the
comparator pivotal trials used, there was a lack of reliable data on
clinical remission among MDD patients for more than the 6-week
study time frame. Therefore, a one-time remission rate application
was allowed in the model, and a non-treatment-speciﬁc relapse
rate for remitting patients was applied for the remainder of the
model. Notably, the additional remission rate and rate of relapse
assumptions were not treatment-speciﬁc, which therefore mini-
mized bias in the model.
Importantly, there were no head-to-head studies for treat-
ments included in the model. Therefore, to ensure data inputs
were comparable, trials with similar inclusion criteria and study
design were selected. Although the trials were similar, there were
a few notable differences including the differing criteria for in-
adequate response among the trials and the 8-week treatment
duration for olanzapine/ﬂuoxetine. While indirect comparisons do
not provide the same level of evidence as head-to-head clinical
comparisons, these results are generalizable to the extent that the
data used are consistent with the realities of clinical practice. Fi-
nally, treatment comparators were limited to branded therapies to
support decision-makers evaluating newly branded products
against others for place in therapy and coverage.
Overall, the model is a simpliﬁed representation of disease
natural history over a 48-week time horizon and may not account
for all possible health states and complications associated with
disease. Resource utilization on treatment was estimated using the
resource use data from previous studies, therefore, calculated
medical costs might be under-/over-estimated compared to the
real-world setting.5. Conclusions
These ﬁndings suggest adjunctive treatment with brexpipra-
zole increase clinical effectiveness based on endpoints of response
and remission compared to other branded adjunctive therapies.
Although total costs were higher, medical care cost savings were
observed with the use of brexpiprazole. Sensitivity analyses
showed all combinations of incremental cost-effectiveness ratios
were in the upper right quadrant, representing a situation where
treatment with brexpiprazole is more costly but also more clini-
cally effective in terms of responders and remitters. These ﬁndings
may be of importance to clinicians and formulary decision makers
when selecting branded adjunctive treatment for MDD.Funding
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